Сравнительный анализ о тдаленных результатов радикальной простатэктомии и дистанционной лучевой терапии у пациентов, страдающих раком предст ательной железы с высоким онкологическим риском
https://doi.org/10.17650/1726-9776-2015-11-2-61-68
Аннотация
В статье представлен сравнительный анализ раковоспецифической выживаемости 202 пациентов, страдающих раком предстательной железы с высоким риском прогрессирования, которым в период с 2005 по 2008 г. была проведена дистанционная 3D-конформная лучевая терапия или радикальная простатэктомия. Методом пропорциональных рисков Кокса определены факторы, влиявшие на отдаленные результаты лечения.
Об авторе
П. Д. ДемешкоРоссия
Список литературы
1. Океанов А. Е., Моисеев П. И., Левин Л. Ф. Статистика онкологических заболеваний в Республике Беларусь. 2003–2012 гг. Под ред. О. Г. Суконко. Минск: РНПЦ ОМР им. Н. Н. Александрова. 2013; 373 с. [Statistics of cancer diseases in the Republic of Belarus. 2003–2012. [A. E. Okeanov, P. I. Moiseev, L. F. Levin. Edited by O.G. Sukonko. Minsk: N. N. Alexandrov Research and Practical Centre of Oncology and Medical Radiology, 2013; 373 p. (In Russ.)].
2. Mohler J. L., Kantoff P. W., Armstrong A. J. et al. Prostate cancer version 2. J Natl Compr Canc Netw 2014;12(5): 686–718.
3. Grossfeld G. D., Latini D. M., Lubeck D. P. et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003;169: 157–63.
4. Yossepowitch O., Eggener S. E., Serio A. M. et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008;53:950–9.
5. Bolla М. Van Tienhoven G., Warde P. et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-years results of an EORTC randomised study. Lancet Oncol 2010;11(11):1066–73.
6. Hanks G. E., Pajak T. F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal ytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol 2003;21(21):3972–8.
7. Roach M., Bae K., Speight J. et al. Short- term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: longterm results of RTOG 8610. J Clin Oncol 2008;26(4):585–91.
8. Warde Р. Mason M., Ding K. et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378(9809):2104–11.
9. Widmark А., Klepp O., Solberg A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373(9660):301–8.
10. Shelley M. D., Kumar S., Wilt T. et al. A systematic review and meta-analysisof randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Canc Treat Rev 2009;35(1):9–17.
11. Rubin D. B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127 (8 Pt 2):757–63. 12. D , Amico A. V., Whittington R., Malkowicz S. B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
12. Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.
13. Thompson I., Thrasher J. B., Aus G. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106–31
14. Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364(18):1708–17.
15. Wilt T. J., Brawer M. K., Jones K. M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367 (3):203–13.
16. Akakura K., Suzuki H., Ichikawa T. et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 2006;36:789–93.
17. Acadamies Io Mot N. Initial National Priorities for Comparative Effectiveness Research. 2009. [Cited 28 Aug 2014.]Available from URL: http://www.iom.edu/Reports/2009/ComparativeEffectivenessResearchPriorities. aspx].
18. Hoffman R. M., Koyama T., Fan K. H. et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst;2013;105:711–8.
19. Sun M., Sammon J. D., Becker A. et al. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int Published online June 20. 2013; http://dx.doi.org/10.1111/bju. 12321.
20. Aizer A. A., Yu J. B., Colberg J. W. et al. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol 2009;93:185–91.
21. Tewari A., Divine G., Chang P. et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy propensity scoring approach [published erratum appears in: J Urol 2007;177:1958]. J Urol 2007;177:911–5.
22. Nguyen P. L., Chen M. H., Catalona W. J. et al. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009;73:659–64.
23. Zelefsky M. J., Yamada Y., Fuks Z. et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028–33.
24. Heemsbergena W. D., Al-Mamganib A., Slotc A. et al. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014;110:104–9.
25. Dearnaley D. P., Jovic G., Syndikus I. et al. Escalated dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014;15:464–73.
26. Zelefsky M. J., Fuks Z., Hunt M. et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166(3):876–81.
27. Miralbell R., Roberts S.A., Zubizaretta E. et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82(1):17–24.
28. Dasu A., Dasu I. T. Prostate alpha/beta revisited an analysis of clinical results from 14 168 patients. Acta Oncol 2012;51(8):963–74.
29. Arcangeli G., Saracino B., Gomellini S. et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78(1):11–8.
30. Prada P. J., Mendez L., Fernandez J. et al. Long-term biochemical results after highdose- rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol 2012;7:31–9.
Рецензия
Для цитирования:
Демешко П.Д. Сравнительный анализ о тдаленных результатов радикальной простатэктомии и дистанционной лучевой терапии у пациентов, страдающих раком предст ательной железы с высоким онкологическим риском. Онкоурология. 2015;11(2):61-68. https://doi.org/10.17650/1726-9776-2015-11-2-61-68
For citation:
Demeshko P.D. Radical prostatectomy versus external beam radiotherapy for high risk prostate cancer: comparison of treatment outcomes. Cancer Urology. 2015;11(2):61-68. (In Russ.) https://doi.org/10.17650/1726-9776-2015-11-2-61-68